麝香保心丸联合银杏达莫注射液对急性心肌梗死溶栓再通患者血浆内皮素-1、超敏C反应蛋白及心功能的影响

The affect of Shexiangbaoxin pill combined with ginkgo-dipyridamolun on ET-1,hs-CRP and cardiac function of the acute myocardial infaration patient with thrombolytic therapy

目的探讨麝香保心丸联合银杏达莫注射液对急性心肌梗死(AMI)溶栓再通患者血浆内皮素-1(ET-1)、超敏C反应蛋白(hs-CRP)及心功能的影响。方法将98例AMI患者随机分为2组,对照组49例给予常规药物及溶栓治疗,治疗组49例在对照组治疗基础上加用麝香保心丸及银杏达莫注射液治疗。4周后采用防免法、胶乳凝集法分别测定2组治疗前及治疗4周后血浆ET-1及hs-CRP水平,同时行心脏超声检查测定2组左室射血分数(LVEF)。结果 2组治疗后ET-1及hs-CRP水平均低于治疗前,且治疗组低于对照组,差异均有统计学意义(P<0.05)。4周后治疗组LVEF水平为(63±11)%显著高于对照组的(51±10)%,差异有统计学意义(P<0.05)。结论麝香保心丸联合银杏达莫注射液能明显改善AMI溶栓再通患者的预后,能改善血管内皮功能、减轻炎性损伤及改善心功能。

Objective To discuss the effect of Shexiangbaoxin pill combined with ginkgo-dipyridamolun on ET-1,hs-CRP and cardiac function of the acute myocardial infaration（AMI） patient with thrombolytic therapy.Methods 98 cases patients with AMI were randomly divided into two groups.Control group（49 cases） were treateded by routine therapy,treatment grout（49 cases） in the control group based on,were given Shexiangbaoxin pill combined with ginkgo-dipyridamolun.After 4 weeks,determined plasma ET-1 and hs-CRP level before treatment and after 4 weeks by anti-free method and latex agglutination of two groups,and determined left ventricular ejection fraction（LVEF） of two groups by cardiac ultrasound.Results After treatment,ET-1 and hs-CRP level of two groups were lower than those before treatment,and treatment group were lower than those of control group,the difference were statistically significant（P〈0.05）.After treatment 4 weeks,the level of LVEF of treatment group[（63±11）%] was significantly higher than that of control group[（51±10）%],the difference was statistically significant（P〈0.05）.Conclusion Shexiangbaoxin pill combined with ginkgo-dipyridamolun can obviously prognosis of AMI patient with thrombolytic therapy,can improve the vascular endothelial function and lessen inflammatory injury and enhance the cardiac function.